6105 or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by email at or by telephone at (800) 747-3924.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at or by telephone at (866) 803-9204 SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at or by telephone at (800) 808-7525, ext. The final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at Alternatively, electronic copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: J.P. The offering was made only by means of a prospectus supplement and accompanying prospectus. The offering was made pursuant to a shelf registration statement, including a base prospectus, filed by RAPT with the Securities and Exchange Commission (SEC), which was declared effective by the SEC on November 16, 2020. and Roth Capital Partners acted as co-lead managers for the offering. Cantor acted as book-running manager for the offering. Morgan, SVB Leerink and Piper Sandler acted as joint lead book-running managers for the offering. The aggregate gross proceeds to RAPT from the offering were approximately $143.7 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares of common stock were offered by RAPT. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share, which includes 568,181 shares issued and sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.
0 kommentar(er)
